title: Randomized, controlled trial of budesonide and prednisone for the treatment of idiopathic inflammatory bowel disease in dogs.
abstract: BACKGROUND
  Budesonide has been used to treat inflammatory bowel disease (IBD) in dogs, but no controlled studies have been performed to evaluate efficacy of this treatment.
  
  
  OBJECTIVE
  To compare budesonide and prednisone for induction therapy of IBD in dogs by using IBD activity index scores and evaluating frequency and severity of owner-reported adverse effects.
  
  
  METHODS
  Forty client-owned dogs with newly diagnosed idiopathic IBD were enrolled between April 2001 and January 2004; 34 dogs completed the 6 week study.
  
  
  METHODS
  Double-blinded, randomized controlled trial. Dogs were randomized to receive either pure powder-based budesonide (3-7 kg: 1 mg PO q24h, 7.1-15 kg: 2 mg PO q24h, 15.1-30 kg: 3 mg PO q24h, >30 kg: 5 mg PO q24h) for 6 weeks or prednisone (1 mg/kg PO q12h × 3 weeks then 0.5 mg/kg PO q12h × 3 weeks). IBD activity index (IBDAI) scores were determined at diagnosis and after 6 weeks of treatment. Pet owners completed weekly questionnaires regarding clinical signs and incidence and severity of adverse effects.
  
  
  RESULTS
  Significant differences in remission rates (>75% decrease in IBDAI scores) were not observed with a remission rate of 78% in the budesonide group and 69% in the prednisone group (P = .70). Frequency of adverse effects was similar between the 2 groups.
  
  
  CONCLUSIONS
  There was no demonstrable difference in remission rates or incidence of adverse effects between prednisone and budesonide for induction therapy of IBD in dogs.
authors.affiliation: Animal Medical Specialists, VRCC, Englewood, CO.
authors.forename: T L
authors.initials: TL
authors.lastname: Dye
authors.forename: K J
authors.initials: KJ
authors.lastname: Diehl
authors.forename: S L
authors.initials: SL
authors.lastname: Wheeler
authors.forename: D S
authors.initials: DS
authors.lastname: Westfall
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001706:Biopsy / Q000662:veterinary; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy / Q000276:immunology*; D004285:Dogs; D004311:Double-Blind Method; D006651:Histocytochemistry / Q000662:veterinary; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011795:Surveys and Questionnaires
chemical_list: D000893:Anti-Inflammatory Agents; D019819:Budesonide; D011241:Prednisone
keywords: CIBDAI; Corticosteroids; Diarrhea; Endoscopy; Vomiting